References
- Paepe P, De Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 2007; 21: 37–43
- Gascoyne R D. Emerging prognostic factors in diffuse large B cell lymphoma. Curr Opin Oncol 2004; 16: 436–441
- The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
- Wilder R B, Rodriguez M A, Medeiros L J, Tucker S L, Ha C S, Romaguera J E, et al. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 2002; 94: 3083–3088
- Wu G, Keating A. Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. Cancer 2006; 106: 247–257
- Lossos I S, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 995–1007
- Shibayama H, Takai E, Matsumura I, Kouno M, Morii E, Kitamura Y, et al. Identification of a cytokine-induced antiapoptotic molecule anamorsin essential for definitive hematopoiesis. J Exp Med 2004; 199: 581–592
- Hatanaka Y, Hashizume K, Nitta K, Kato T, Itoh I, Tani Y. Cytometrical image analysis for immunohistochemical hormone receptor status in breast carcinomas. Pathol Int 2003; 53: 693–699
- Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
- Hao Z, Li X, Qiao T, Du R, Hong L, Fan D. CIAPIN1 confers multidrug resistance by upregulating the expression of MDR-1 and MRP-1 in gastric cancer cells. Cancer Biol Ther 2006; 5: 261–266
- Shipp M A, Ross K N, Tamayo P, Weng A P, Kutok J L, Aguiar R C, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74
- Biasoli I, Morais J C, Scheliga A, Milito C B, Romano S, Land M, et al. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses. Histopathology 2005; 46: 328–333
- Barrans S L, Carter I, Owen R G, Davies F E, Patmore R D, Haynes A P, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136–1143
- Iqbal J, Neppalli V T, Wright G, Dave B J, Horsman D E, Rosenwald A, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961–968
- Krause D S, Van Etten R A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172–187
- Kuroki M, Huang J, Shibaguchi H, Tanaka T, Zhao J, Luo N, et al. Possible applications of antibodies or their genes in cancer therapy. Anticancer Res 2006; 26: 4019–4025
- Savage D G, Antman K H. Imatinib mesylate – a new oral targeted therapy. N Engl J Med 2002; 346: 683–693
- Held G, Poschel V, Pfreundschuh M. Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther 2006; 6: 1175–1186
- O'Connor O A, Hamlin P. New drugs for the treatment of advanced-stage diffuse large cell lymphomas. Semin Hematol 2006; 43: 251–261
- Shivakumar L, Armitage J O. Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma 2006; 6: 455–457
- Winter J N, Weller E A, Horning S J, Krajewska M, Variakojis D, Habermann T M, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207–4213
- Chanan-Khan A. Bcl-2 antisense therapy in B-cell malignancies. Blood Rev 2005; 19: 213–221
- Polo J M, Dell'Oso T, Ranuncolo S M, Cerchietti L, Beck D, Da Silva G F, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 2004; 10: 1329–1335
- Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 2004; 112: 79–84